Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by jopatcloon Jan 29, 2023 10:21am
206 Views
Post# 35252594

NANCE Healthcare dealmaking will heat up in 2023 VPT year $$

NANCE Healthcare dealmaking will heat up in 2023 VPT year $$"Healthcare dealmaking will heat up in 2023 with plenty of corporate cash, PE 'dry powder'"
Increasing transaction volumes and players embracing value-based care—coupled with large levels of corporate cash and private equity "dry powder"—are leading to continued expansion for deal volumes in 2023, according to a new analysis from PwC. (Dilok Klaisataporn/GettyImages)
https://www.fiercehealthcare.com/finance/expect-busy-year-healthcare-dealmaking-plenty-corporate-cash-pe-dry-powder

Economic headwinds and recessionary fears will not slow down healthcare dealmaking next year coming off a robust M&A market in 2022.

 
 

Increasing transaction volumes and players embracing value-based care—coupled with large levels of corporate cash and private equity "dry powder"—are leading to continued expansion for deal volumes in 2023, according to a new analysis from PwC.

 
 

The accounting and consulting firm forecasts a strong outlook for health services M&A deals in 2023 with companies actively exploring M&A, divestitures and other transactions, said Nick Donkar, PwC’s U.S. health services deals leader.

"The deal market in 2022 was fairly robust coming off an unprecedented banner year, which was 2021. Obviously, 2021 was the highest deal volume we've experienced from a health services perspective. We're happy to see the health of the overall market, no pun intended, with respect to the level of volume and activity that has been exhibited thus far in 2022," he said in an interview.

He added, "The fact that we've got a lot of assets trading in this marketplace is good for all parties. As people reevaluate their strategies, they want to participate in a healthy ecosystem. The deal volume in this sector was fairly heavy and continues to be so, which speaks to the overall attractiveness of the market for healthcare."

 

In 2021, there were 1,996 health services M&A deals at a value of $217 billion, which marked a high for the sector.

Despite the economic downturn, the healthcare sector and health services in particular has proven to be nearly "recession-proof," Donkar noted, due to "innovation, technology and investment dollars that continue to funnel in to enhance patient care."  

While sufficient headwinds existed in the deal markets to potentially stall health services deal activity in 2022, the sector performed well and is poised to further expand volume in 2023 between reshaping portfolios, divestitures and a flurry of PE "dry powder," according to Donkar.

Megadeals, trading multiples and overall deal values in the sector have not been immune to interest rate hikes and fears of an economic downturn.

<< Previous
Bullboard Posts
Next >>